Hubei Biocause Pharmaceutical shares delisted from Shenzhen exchange

Hubei Biocause Pharmaceutical Co., Ltd. announced the termination of its shares' listing on the Shenzhen Stock Exchange, effective September 25, 2025. The decision follows the company's proactive application on September 4, 2025, which was based on a resolution passed at an extraordinary general meeting on August 25, 2025. As an active delisting, there will be no delisting grace period.

The company's ordinary A-shares, traded under the former short name *ST Tianmao and stock code 000627, will be delisted within five trading days from the announcement date. Investors, brokerages, and other market participants are advised to settle all stock-pledged repurchase, agreed repurchase, margin trading and securities lending, and Shenzhen-Hong Kong Stock Connect business before the delisting. Judicial freeze operations expiring after the delisting date should be renewed proactively by relevant authorities.

Following delisting, Hubei Biocause Pharmaceutical's shares will transfer to the national SME share transfer system's delisted company section for trading. The company has appointed Great Wall Guorui Securities Co., Ltd. as its transfer agent to handle share confirmation, registration, and custody, with further details to be announced on the National Equities Exchange and Quotations (NEEQ) website.